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ABSTRACT
Background: Alendronate Sodium (ALDS) is the drug of choice for treatment of osteoporosis. However, 
50% of the osteoporotic patients ceased the treatment within the first year due to its potential side effect 
on the gastrointestinal tract (GIT).
Objective: The current study aimed to utilize nanotechnology to develop a nano-oral liposomal prepara-
tion containing biodegradable polymer (Starch) that enhance the drug prosperities.
Methods: Nanoliposomes of ALDS were prepared using different concentrations of solubilized starch 
(0.1 - 0.5 g ) by thin film hydration method. A new method of alendronate quantitative determination 
was used to overcome the obstacle of its determination by using a new highly sensitive derivatization 
method. The selected formula was visualized using TEM, in vitro release studies and Stability study was 
also carried out.
Furthermore, ulcerogenicity studies were performed to compare between the optimum prepared for-
mula and a standard nonliposomal ALDS.
Results: Six nano-oral liposomal formulations were prepared with zeta potentials ranging from -12 mV 
to -39 mV and a particle size ranging from 94 nm to 298 nm. The encapsulation efficiency studies dem-
onstrated that the amount of ALDS entrapped within liposomes increased with increasing starch con-
centration. The stability studies confirmed the role of starch in increasing the stability of the prepared 
liposomes. In vitro release studies have demonstrated a relative delay in ALDS releases from the lipo-
some core.
Ulcerogenicity studies proofed that the prepared formula has a significant gastric tolerance.
Conclusion: a novel liposomal formula of ALDS was developed with better tolerability. However, fur-
ther clinical investigations are necessary to evaluate its therapeutic effectiveness.
Keywords: Liposome, Alendronate Sodium, starch, Ulcerogenicity studies
RESUMEN
Antecedentes: El alendronato sódico (ALDS) es el fármaco de elección para el tratamien-
to de la osteoporosis. Sin embargo, el 50% de los pacientes osteoporóticos cesaron el tratamien-
to en el primer año debido a su posible efecto secundario en el tracto gastrointestinal (GIT). 
Objetivo: El presente estudio tiene como objetivo utilizar la nanotecnología para desarrollar una preparación 
liposomal nano-oral que contiene polímero biodegradable (almidón) que mejoran la prosperidad de la droga. 
Métodos: Se prepararon nanoliposomas de ALDS utilizando diferentes concentraciones de almidón so-
lubilizado (0,1 - 0,5 g) mediante un método de hidratación de película delgada. Se utilizó un nuevo 
método de determinación cuantitativa de alendronato para superar el obstáculo de su determinación 
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utilizando un nuevo método de derivatización altamente sensible. 
La fórmula seleccionada se visualizó utilizando TEM, estudios de 
liberación in vitro y se realizó también un estudio de estabilidad. 
Además, los estudios de ulcerogenicidad se realizaron para comparar 
entre la fórmula óptima preparada y un estándar no liposomal ALDS. 
Resultados : Se prepararon seis formulaciones liposomales 
nano-orales con potenciales zeta que oscilaban entre -12 mV 
y -39 mV y un tamaño de partícula que variaba de 94 nm a 298 
nm. Los estudios de eficacia de la encapsulación demostraron 
que la cantidad de ALDS atrapada dentro de los liposomas au-
mentaba con el aumento de la concentración de almidón. Los 
estudios de estabilidad confirmaron el papel del almidón en 
el aumento de la estabilidad de los liposomas preparados. Los 
estudios de liberación in vitro han demostrado un retraso re-
lativo en las liberaciones de ALDS del núcleo de liposomas. 
Los estudios de ulcerogenicidad demostraron que la fór-
mula preparada tiene una tolerancia gástrica significativa. 
Conclusión: se desarrolló una nueva fórmula liposomal de ALDS 
con mejor tolerabilidad. Sin embargo, otras investigaciones clínicas 
son necesarias para evaluar su efectividad terapéutica.
Palabras clave: Liposoma, Alendronato Sodio, almidón, Estudios 
de ulcerogenicidad
INTRODUCTION
ALDS is globally used for the treatment and/or preven-
tion of postmenopausal osteoporosis and glucocorticoid-
induced osteoporosis1. It belongs to BCS III class (high 
solubility and low permeability). Low oral bioavailability 
(under 1%) is one of the most important disadvantages of 
ALDS. That is caused by several factors such as low perme-
ability due to its negatively charged molecules (AL belongs 
to the 3rd class of biopharmaceutical classification system); 
short plasma half-time (t½ 0.5-2 h)2 and its chelation by Ca2+ 
ions which results in non-absorbable complexes .
There is a need to develop more efficient delivery systems 
of ALDS to avoid the upper gastrointestinal tract irritation3. 
Symptoms of upper gastrointestinal tract irritation includ-
ing esophagitis, vomiting, epigastric pain, nausea, and 
dyspepsia, have been reported with use of ALDS sodium 
tablets. Esophageal adverse effects have been reported with 
use of ALDS tablet, some of which were more severe and 
dangerous than that observed in controlled clinical trials. 
It is important to note that some cases of esophagitis and 
also esophageal ulceration were related to ALDS tablet use; 
many of these cases have occurred in patients who did not 
follow the recommended instructions or who continued 
using ALDS in spite of worsening esophageal symptoms. 
About 50% of patients discontinue taking ALDS tablets 
during the first year of treatment due to its gastrointestinal 
tract (GIT) side effects.
Research on ALDS is a challenge as its quantitative de-
termination is sophisticated From the analytical point 
of view, sodium ALDS assay is a difficult task due to the 
lack of chromophores absorbing photons between 200 and 
800 nm4. One of the most promising delivery systems is li-
posomes formulations. The liposome is one of the poten-
tial drug delivery systems applying nanotechnology to 
potentiate the therapeutic efficacy and reduce toxicities of 
conventional medicines, they are consist of lipid vesicles 
from natural and synthetic phospholipids of different sizes, 
loading capacities, and compositions. They are defined as 
vesicular structures consisting of amphiphilic, in vivo de-
gradable phospholipids and can thus encapsulate a broad 
range of effective agents, that effective agents may have hy-
drophilic, lipophilic or even amphiphilic nature. There are 
three main categories of liposomes: small unilamellar vesi-
cles, large unilamellar vesicles, and multilamellar vesicles.
That classification is based on liposomes lamellarity and 
size. Liposomes have been used as carrier systems for the 
delivery of vaccines, hormones, and therapeutic drugs, due 
to the easy preparation, biodegradability, good biocom-
patibility, and commercial availability of liposomes5. Ear-
lier studies have discovered that liposomal drug delivery 
systems improved the cellular absorption of highly hydro-
philic drugs such as acyclovir and cefotaxime6. Nanoparti-
cles may be comprised of several kind materials being clas-
sified as nondegradable and biodegradable7.
Recently, Polysaccharide-based nanoparticles have re-
ceived high attention as very promising nanoparticulate 
drug delivery systems due to their unique potentials as in-
ert excipient biopolymer8. The use of starch nanoparticles 
is, therefore, receiving a significant amount of attention 
due to their good biocompatibility and biodegradability9. 
Starch is relatively pure and does not need much purifica-
tion processes like other naturally- occurring biopolymers 
e.g. celluloses and gums 10.
By optimizing the right combination of liposomal and 
polymer characteristics, it is possible to develop delivery 
systems for the specific, prolonged, and controlled release11. 
High amylose corn starch has high sustained release prop-
erties due to its excellent gel-forming capacity12. The mech-
anism of drug release from such gel-forming matrix as-
sumes a controlled passage of drug molecules through the 
obstructive gel layer, gel structure, and matrix. When starch 
granules are heated in the aqueous environment, granules 
start swelling and gelatinization takes place at about 55- 
80°C depending on the type of starch used13. Upon cool-
ing starch, it begins to undergo retro gradation whereby 
the starch molecules begin to re-associate in an ordered 
structure. Cross-linked starch nanoparticles were used for 
drug delivery and Indomethacin was taken as the model 
drug14. Recently, efforts were made to develop alternative 
formulations for the oral administration of ALDS, with a 
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goal of decreasing GI adverse events and possibly increas-
ing compliance15.
MATERIALS AND METHODS
Materials:
aLDS was a gift from Unipharma Pharmaceutical Indus-
tries (Egypt). Soya bean phosphatidylcholine, cholesterol, 
and 2-mercaptoethanol (2ME) were purchased from Sigma-
Aldrich (USA). Starch was kindly supplied by Starch and 
Glucose Company (Egypt). Chloroform, methyl alcohol, 
and sodium hydroxide were obtained from El-Nasr Phar-
maceutical Co. (Egypt). All other chemicals and reagents 
used were of pharmaceutical grade.
Methods:
Quantitative analysis of ALDS:
Double distilled water was used for the preparation of all 
solutions.
-Preparation of standard stock and test solutions:
The stock solution was prepared by dissolving 10 mg of 
ALDS sodium in 10 ml of 0.05 M NaOH and the prepared 
solution is used with 48 hours. The working solution of the 
derivatizing reagent was prepared by dissolving 10 mg of 
o-phthalaldehyde (OPA) in 2 ml of 0.05 M NaOH, then 50 
μl of 2-mercaptoethanol (2ME) solution were added. This 
solution was freshly prepared for each experiment.
The total solution volume was completed to 10 ml using 
0.05M NaOH. Aliquots (0.0, 0.4, 0.8, 1.2, 1.6, 2 and 2.4 μM) 
of this solution were transferred to a 2ml vial. 100 μl of the 
OPA/2ME reagent was added to each vial and then the vol-
umes were completed to 2 ml with 0.05 M NaOH. 1mg/
ml ALDS solution was prepared using 0.05 M NaOH as a 
solvent.
-Spectrofl uorometric determination of ALDS:
The reported methods for quantitation of ALDS are all ex-
pensive and time-consuming16. The procedure used in this 
study was based on the reaction of a primary amino group 
of ALDS ion with o-phthalaldehyde (OPA) in alkaline me-
dium giving a fl uorescent adduct according to the follow-
ing equation17:
A calibration curve was constructed by plotting fl uores-
cence intensity (in arbitrary units) versus concentration. 
The linear portion of the curve lies within the concentra-
tion range of 0.0-2.4 μM where the inner-fi lter effect was 
minimum. The limit of quantifi cation of the method was 29 
nanomolar as reported earlier.
-Preparation of calibration curve:
Liposomes were prepared by a modifi ed thin fi lm hydra-
tion method18. Phosphatidylcholine (0.6 g) and cholesterol 
(0.2g) were mixed and then the mixture was dissolved in 
chloroform/methanol mixture (in a volume ratio 2:3)19. The 
resulting mixture was dried up to thin lipid fi lms on the 
inner wall of the fl ask using a rotary evaporator under vac-
uum. ALDS (50 mg) was dissolved in 10 ml isotonic NaCl 
solution, then different amounts of starch were added in in-
cremental amounts (0.0 g to 0.5 g) with proper mixing, and 
the solution was heated at 55 to 65ºC for 10 to 15 min. The 
produced lipid thin fi lm was hydrated with the prepared 
ALDS sodium solution and agitated for a suitable period 
above 65ºC using rotary evaporator. Samples were sonicat-
ed for few minutes and centrifuged at 18000 rpm for 30min. 
Finally, separation of supernatant has been performed.
Preparation of liposomes:
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Liposomes were prepared by a modified thin film hydra-
tion method18. Phosphatidylcholine (0.6 g) and cholesterol 
(0.2g) were mixed and then the mixture was dissolved in 
chloroform/methanol mixture (in a volume ratio 2:3)19. The 
resulting mixture was dried up to thin lipid films on the 
inner wall of the flask using a rotary evaporator under vac-
uum. ALDS (50 mg) was dissolved in 10 ml isotonic NaCl 
solution, then different amounts of starch were added in in-
cremental amounts (0.0 g to 0.5 g) with proper mixing, and 
the solution was heated at 55 to 65ºC for 10 to 15 min. The 
produced lipid thin film was hydrated with the prepared 
ALDS sodium solution and agitated for a suitable period 
above 65ºC using rotary evaporator. Samples were sonicat-
ed for few minutes and centrifuged at 18000 rpm for 30min. 
Finally, separation of supernatant has been performed.
Determination of vesicle size:
After dilution with water, both vesicles size and size dis-
tribution were determined by the dynamic light scattering 
method using a Malvern Mastersizer(UK).
Zeta potential determination:
Zeta potentials of liposomes were determined from elec-
trophoretic mobility of the particles using an instrument 
model Malvern Zetasizer 2000(Malvern, UK) [27].
Entrapment efficiency (EE) determination:
The liposomes were separated from the supernatant then 
the concentrations of ALDS in isotonic NaCl solutions were 
determined spectrofluorometrically after derivatization us-
ing spectrofluorometry (Shimadzu, Kyoto, Japan) at λmax 
470 nm.20 The entrapment efficiency expressed as entrap-
ment percentage was calculated using the following equa-
tion:
Entrapment Efficiency % = (Entrapped drug / Total drug) 
× 100
In vitro drug release study:
The drug release studies were carried out in 250 ml beak-
ers containing phosphate buffered saline pH 7.4 as at 37 
C, absorption was found to be chiefly in the upper part of 
the small intestine and hence pH 7.4 is more consistence 
with the small intestine pH. The beaker content was con-
stantly stirred at 150 rpm with a small magnetic stirrer. Di-
alysis membrane was taken and one end of the membrane 
was sealed. After separation of entrapped ALDS liposome 
dispersion was filled in the dialysis membrane and an-
other end was closed. The dialysis membrane containing 
the sample was suspended in the medium. Aliquots were 
withdrawn (5 ml) at selected time intervals (0.5, 1, 2, 3, 4, 6, 
8 and 24 h), filtered and the apparatus was immediately re-
plenished with the same quantity of fresh buffer medium. 
The Aliquots were measured for the amount of the drug by 
using the previous stated derivatizing agents, all reagents 
are freshly prepared.
Stability study:
The in vitro stability was tested for two prepared liposomes 
formulations F1 (free starch liposomes) and F6 (liposomes 
with the highest concentration of starch) by monitoring the 
particle size and zeta potential for over one month at stor-
age temperatures of 4-8 C and 20-25C. To determine the ca-
pability of the prepared formulas to retain the drug within 
the vesicles throughout the storage period, F1 and F6 were 
centrifuged and the entrapment efficiency was determined 
as described earlier in the entrapment efficiency determina-
tion section.
Transmission electron microscopy (TEM):
The optimum prepared liposome formula (F6) morphol-
ogy was visualized by transmission electron microscopy 
(TEM). The prepared liposomes were diluted with double-
distilled water then one drop of the prepared formula was 
added onto hydrophobic carbon. The samples were air 
dried for few minutes at room temperature. The specimens 
were stained with uranyl acetate for 4 min and the excess 
amount of uranyl acetate was blotted using filter paper. 
After drying, the liposomes on a hydrophobic carbon grid 
were directly observed and photographs were captured us-
ing Transmission Electron Microscope (JEOL Ltd., Tokyo, 
Japan).
Ulcerogenicity study:
Based on the entrapment efficiency, stability and in vitro 
drug release studies; F6 was selected to be compared with 
alendronate solution of the same concentration. The ulcero-
genicity study was performed for both of them to evalu-
ate their gastric -ulcerogenic potential. Three groups (A, 
B and C) of rats were administered each consist of 6 rats, 
rats weights were ranging between 150 and 200 gm. Group 
A represented the control group, group B represented F6 
receiving rates while group C represented rats which re-
ceived non-liposomal alendronate solution. Observation 
of the gastric mucosa for the presence of lesions following 
oral administration of 20 mg/kg of the tested formulas was 
used as an indication for the ulcerogenic effects. The rats in 
group B and C were administered alendronate (20 mg/kg) 
for 7 days, while group A rats were receiving saline, then all 
the rats have been killed, the stomachs have been removed, 
and the extent of tissue damage was evaluated microscopi-
cally. Ulcer index was calculated to analysis the effect on 
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the stomach mucosa. The ulcer index represents the total 
sum of Ulcers numbers, incidence percentage and severity 
of the resulted ulcers after the oral administration the drug.
Results and discussion:
Analytical procedure
ALDS sodium has no characteristic absorption or emission 
chromophores, so its estimation represents a challenge20 
due to the lack of chromophores absorbing photons be-
tween 200 and 800 nm. The reactions of OPA with amino 
compounds in the presence of nucleophilic agents to give 
isoindole derivatives are used for the analytical determina-
tion of primary amines and amino acids.
Calibration curve:
Figure 1 shows a calibration curve, based on plotting OPA- 
ALDS adduct fluorescence intensity versus ALDS concen-
tration. The calibration curve was linear over the concen-
tration range of 0.0-2.4 μM and the limit of quantification of 
the method was 29 nanomolar that is comparable with the 
previous studies21.
Figure 1: Calibration curve based on OPA- ALDS adduct fluorescence intensity versus ALDS concentra-
tion.
Vesicles size analysis:
Liposomes particle sizes ranged from 94 nm to 298 nm and 
that range was increasing with elevating starch concen-
tration as illustrated in table2. This wide size distribution 
range may indicate liposomes aggregation22.
It is noticed that with increasing starch concentration there 
is a relative increase in the size of liposomes that may be at-
tributed to the formation of the starch outer layer around li-
posomes vesicles that results are comparable with previous 
studies which investigated the effect of natural polymers 
incorporation on liposomes physical characters23.
Zeta potential:
Zeta potential has frequently been used to characterize col-
loidal drug delivery systems. It is a measure of the particles 
surface electrical charge. The zeta potential is a good indi-
cator of the stability of the colloidal system. If all the par-
ticles in suspension have a large positive or negative zeta 
potential, then they will repel each other, and there will be 
no affinity for the particles to agglomerate. The Zeta poten-
tial is a significant parameter which influences liposomal 
behavior. In vivo, the surface charge density influences the 
liposomes’ distribution, and in vitro, a high potential may 
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contribute to the liposomes physical stability by decreas-
ing the rate of aggregation. ALDS liposomes without starch 
showed a slight negative zeta potential, in agreement with 
early reports24.
It was obvious that coating of liposomes by starch shifted 
the zeta potential values, from slightly negative to larger 
negative. The results show that liposomes had relatively 
large zeta values after being coated with 0.1–0.5% w/v 
starch solutions. The liposomes had a zeta potential rang-
ing from -12 mV to -39 mV as shown in table 3 giving good 
stability of the liposomes25.
Entrapment efficiency (EE):
Concerning the effect of starch content on the liposome 
encapsulation efficiency of ALDS, results showed that the 
percentage entrapment efficiency of ALDS increased by 
increasing starch content. The percentage entrapment ef-
ficiencies of ALDS liposomes were 46.5%, 60.9%, 67.2%, 
72.1%, 76.3% and 78.5% for the starch concentration ra-
tios of 0 %, 0.1%, 0.2%,0.3%,0.4%, and 0.5% respectively as 
shown in Table 4.
EE% is used to evaluate the effect of using different con-
centrations of starch during formulation. According to 
previous results, upon increasing the starch content, the 
nanoliposomes become more stable and the permeability 
decreases. This leads to more drug retention due to drug 
entrapment through the obstructive gel matrix26. The same 
results were obtained when other natural polymers such as 
chitosan are used in the liposome preparation.
The In vitro release study:
Figure 2: in vitro drug release curve representing cumula-
tive drug release for the pure drug formula and the other sex 
prepared formula (F1 to F6)
The drug release study from the six nano-liposomal for-
mulations was studied and compared to the pure drug as 
shown in (Fig. no. 2). Liposomal formulation exhibit slow 
release that may be attributed to the rigidity of the liposome 
membrane which will increase permeability barrier and 
so reduce the drug loss rate. Moreover, It was found that 
the formulation F1 which is starch free has faster release 
comparing with the formulation that contains starch that 
maybe due to the sterical surface protection which slows 
down the macromolecules adsorption to the liposomal sur-
face and hence starch suppresses clearly the elimination of 
the drug-carrying system from blood by the phagocytes.
The stability of liposomes at two different storage tempera-
ture ranges, 4-8 C, and 20-25 C, was evaluated in terms of 
size, zeta potential, and entrapment efficiency. As shown 
in Table 5, F6 stored at 4-8 C did not show any significant 
change in the amount of entrapped drug; but around 11.5 
% drug was lost when stored at 20-25 C for one month 
while F1 formula after storage at 4-8 C showed a negligible 
change in the amount of entrapped drug while after stor-
age at 20-25 C about 21.5% drug was lost. Thus at a higher 
temperature, ALDS was leaching out of the liposomes, 
that is consistent with earlier observations that at a higher 
temperature, the permeability and the fluidity of phospho-
lipid bilayer increases27. Earlier reports showed that coat-
ing with natural polymers confers stability and enhances 
the dispersability of particulate systems in water. This may 
explain the stability of the F6 formula compared with F1.
After one month storage of both F1 and F6, there was a 
slight increase in the particle size of F6 while there was 
no significant change in the particle size of F1, confirming 
the colloidal stability of F1 and F6 formulations. The slight 
change in the particle size of F6 may be attributed to the 
slight agglomeration of liposomes. While the zeta potential 
of F1 didn’t show significant change, the zeta potential of 
F6 showed slight decrease that might be attributed to the 
coated layer dissociation.
TEM:
Liposome morphology was visualized by TEM. Figure 
3 shows a liposome outer shape images of the optimum 
formula (F6) under different magnification power. Cumu-
lative data obtained by TEM showed that the vesicles are 
well-defined and spherical in shape. There is an agglomera-
tion of excess amounts of starch as appeared in the images, 
the excess amount of starch was incorporated randomly in 
the voids between liposomes and results in few agglom-
erations, that result usually occurred upon using of natu-
ral polymers such as starch and chitosan during liposomes 
preparation28.
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Ulcerogenicity study:
The results showed that Formula 6 has superior safety and 
gastric tolerability compared to the pure drug as shown in 
table 6 and fig. 4. Clearly, Formula 6 demonstrated a re-
markable enhancement in ulcer index (UI = 3.05) in compar-
ing with an Alendronate solution (UI = 13.21). Encapsula-
tion of several orally taken active ingredients in liposomes 
provides protection against both intestinal and gastric ul-
ceration29. Our results were in agreement with Soehngen 
et al., who proved that the liposomal encapsulation of in-
domethacin provides an obvious protection against ulcera-
tion when it was orally administered to rats30 and also other 
studies have illustrated that liposomal encapsulation may 
have a clear effect on reducing GIT side effects e.g ulcera-
tion31. Furthermore, starch has an effect for stomach protec-
tion, acts as a demulcent and also has a soothing effect on 
the GIT mucosa32.
Figure 3: TEM images showing ALDS liposomes (F6) with different magnification scale.
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Figure 4: Pictures of rats stomach mucosa treated with F6(c) compared to F1(B) and control(A)
The decrease in side effects of the newly prepared formulas due to several factors including:
(i) The syrup-like nature of the current formulas, being of viscous mass, may remain in the first portion of the intestine for a 
longer time and if administered after cooling in a refrigerator, improved palatability is expected. This also reduces the transit 
time and hence increases the patient compliance(33).
(ii) Colloidal starch has a soothing effect on the stomach and hence decrease the potential gastric upset(34)
(ii) ALDS is irritating for stomach(35), and its entrapment into the liposome may have an effect on decreasing its potential side 
effects.
CONCLUSION
In an attempt to develop an oral liposomal delivery system, 
natural polymer (starch) was used as means of improving 
liposomal properties. The liposomes of ALDS were pre-
pared using phosphatidylcholine /cholesterol and different 
amounts of starch. ALDS /starch mixture was entrapped 
into the vesicles and excess starch coated the vesicles lead-
ing to further improvement of encapsulation efficiency and 
in-vitro stability. Formulation F6 showed high encapsula-
tion efficiency with minimum particle size and drug release 
over an 8 h. Furthermore, F6 has shown better gastric tol-
erability in comparison with the pure drug. Consequently, 
this new formula of liposomes appears to be an effective 
drug delivery system for alendronate and with better tol-
erability and supposed to give greater bioavailability. It is 
predicted that the novel prepared formulas have fewer side 
effects due to several factors including:
(i) The syrup-like nature of the current formulas, being of 
viscous mass, may remain in the first portion of the intes-
tine for a longer time and if administered after cooling in 
a refrigerator, improved palatability is expected. This also 
reduces the transit time and hence increases the patient 
compliance33.
(ii) Colloidal starch has a soothing effect on the stomach 
and hence decrease the potential gastric upset34
(ii) ALDS is irritating for stomach35, and its entrapment into 
the liposome may have an effect on decreasing its potential 
side effects.
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Table 1: Liposomes formulations
Formula no. Phosphatidylcholine (gm( Starch (g ( Cholesterol (g (
1 0.6 0 0.2
2 0.6 0.1 0.2
3 0.6 0.2 0.2
4 0.6 0.3 0.2
5 0.6 0.4 0.2
6 0.6 0.5 0.2
Table 2: Particle size distribution of the prepared liposomes
Formula no.
Starch concentration
(%)
Particle size
(nm)
Mean polydispersity 
index(PDI)
1 0 94±4.3 0.27±0.7
2 0.1 191±6.1 0.14±0.9
3 0.2 225±5.9 0.17±0.8
4 0.3 242±7.1 0.19±0.4
5 0.4 278±2.2 0.29±1.3
6 0.5 298±3.5 0.07±0.2
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Table 3: Zeta potentials of liposomes formulas
Formula 
Formula
no.
Zeta Zeta SD
Zeta
potential
(-mV)
Data
Data retention
(%)
1 -12±0.49 91
2 -22±1.67 87
3 -25±0.76 68
4 -29±1.81 86
5 -34±1.1 89
6 -39±2.19 94
Table 4: Percentage entrapment efficiency (EE%) of ALDS by liposomes of different starch concentrations
Liposomal formula
Entrapment efficiency
(% w/w)
± SD
1 46.5 ±1.89
2 60.9 ±3.05
3 67.2 ±1.63
4 72.1 ±1.89
5 76.3 ±1.51
6 78.5 ±1.32
Table 5: Particle size, zeta potential, and entrapment efficiencies for F1 and F6 liposomal formulas
Liposomal formula F1 F6
Stage initial After one month Initial After one month
Temperature 4-8 °C 20-25°C 4-8 °C 20-25 °C
Particle size (nm) 94-170 98-178 103-184 110-1906 134-1993 154-2057
Zeta potential (mV) -12±0.49 -10±0.89 -8±0.25 -39±2.19 -33±.67 -27±1.28
Entrapment efficiency
(%)
46.5±1.89 43±1.19 25±2.16 78.5±1.32 74.5±1.42 67±0.51
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Table 6: Ulcerogenic effects of F1 and F6
Formula Number of ulcers (average) Ulcer index*
Pure drug
6
Control
6.5
0.6
-
13.21
3.05
Nil
*
